News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
10-May-2013 - Epigenomics AG (ECX) announced its financial results for the first quarter ending March 31, 2013. U.S. Food and Drug Administration (FDA) accepted Premarket Approval (PMA) submission for Epi proColon® and granted priority review status Revenue Q1 2013 increased 46% compared to Q1 2012 New ...
22-Mar-2013 - Epigenomics AG announced its results for the financial year ended 31 December 2012 and provided an outlook for 2013. 2012 Financial results 2012 revenue amounted to EUR 1.0 million (2011: EUR 1.4 million) generated from product sales of Epi proColon® kits, royalty payments, licensing income and ...
09-Jan-2013 - Epigenomics AG announced that it has submitted the fourth and final module of its Premarket Approval (PMA) to the United States Food & Drug Administration (FDA) for its blood-based Epi proColon® test for the detection of colorectal cancer in December 2012 as previously indicated, thereby ...
26-Sep-2012 - The Supervisory Board of Epigenomics AG and its current CEO Geert Walter Nygaard agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012.The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board member of the company and ...
19-Mar-2012 - Epigenomics AG announced that it was decided to propose to the shareholders of the company at its upcoming Annual General Meeting (AGM) on May 2, 2012 to vote in favor of a reduction of the size of the Supervisory Board from currently six to three members. Furthermore, the company’s Chairman, ...
17-Feb-2012 - Epigenomics AG announced the results from a study conducted in collaboration with Professor Dr. Béla Molnár and his team from the 2nd Department of Internal Medicine of Semmelweis University in Budapest, Hungary. In the study, the blood based detection of methylated Septin9 in colorectal cancer ...
09-Jan-2012 - Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent cohorts, ...
06-Jan-2012 - Epigenomics AG announced that it has submitted the first module of its premarket approval (PMA) submission to the US Food and Drug Administration (FDA) on December 30, 2011.On December 30, 2011 Epigenomics has initiated the process of gaining US regulatory approval of its colorectal cancer (CRC) ...
14-Dec-2011 - Epigenomics AG reported the completion of the clinical validation study for its second-generation colorectal cancer blood test Epi proColon in the U.S. The study was designed to measure the clinical performance of Epi proColon for the detection of colorectal cancer in comparison to colonoscopy ...
12-Aug-2011 - Epigenomics AG released plans to restructure its organization and heighten the focus of its activities on the key U.S. market. Operations at the Epigenomics AG headquarters in Berlin, Germany, as well as at its subsidiary Epigenomics Inc. in Seattle, WA, U.S.A., are affected by the restructuring ...
© 1997-2024 LUMITOS AG, All rights reserved